Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 721 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Prescreener database
Other
Lead sponsor
Global Alzheimer's Platform Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
1,555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
San Diego, California • Santa Ana, California • Aventura, Florida + 13 more
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Glendale, California • Gainesville, Florida • Hallandale, Florida
Conditions
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Alzheimer's Disease
Interventions
Leronlimab (700mg)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus Delivery of NGF
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Diego, California • Chicago, Illinois
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
186
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
Interventions
Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer Disease, Frontotemporal Degeneration (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), Mixed Etiology Dementias (MED), Mild Cognitive Impairment (MCI)
Interventions
Problem Solving Training
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
College Station, Texas • Dallas, Texas • Edinburg, Texas
Conditions
Alzheimer Disease
Interventions
NP001, Placebo
Drug
Lead sponsor
Beau Nakamoto
Other
Eligibility
55 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Honolulu, Hawaii
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x, Placebo
Drug
Lead sponsor
CERESPIR
Industry
Eligibility
18 Years to 79 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
St. Petersburg, Florida • Eatontown, New Jersey • Monroe Twp, New Jersey + 2 more
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Recruiting No phase listed Observational Accepts healthy volunteers

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting Not applicable Interventional

OTC Hearing Aid and MCI

NCT06112860
Conditions
Hearing Loss, Mild Cognitive Impairment, Alzheimer Disease and Related Dementias (ADRD)
Interventions
Over the counter hearing aid, Communication Strategies Information/Counseling
Device · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • La Crosse, Wisconsin • Madison, Wisconsin
Completed Phase 3 Interventional Results available

Hormone and Information Processing Study

NCT00539305
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Completed No phase listed Observational Accepts healthy volunteers

A Study of Brain Aging in Vietnam War Veterans

NCT01687153
Conditions
Traumatic Brain Injury, Post Traumatic Stress Disorder, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 90 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
19
States / cities
Sun City, Arizona • Irvine, California • La Jolla, California + 14 more
Conditions
Pain, Chronic, Dementia, Mild, Mobility Limitation, Physical Disability, Osteo Arthritis Knee, Mild Cognitive Impairment
Interventions
Tailored Physical Activity Program
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Plasma p-tau risk disclosure, Standard risk disclosure
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Illinois
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Conditions
Alzheimer's Disease
Interventions
Piromelatine 20 mg, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
60 Years to 85 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
32
States / cities
Costa Mesa, California • Long Beach, California • San Diego, California + 21 more
Conditions
Alzheimer Disease
Interventions
3APS
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
50 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 40 more
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Memory Training, Kundalini yoga and meditation
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alzheimer Disease
Interventions
SAM-531, placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Delray Beach, Florida • Hallandale, Florida • St. Petersburg, Florida + 4 more